Godavari Biorefineries Limited (GBL) reported a resilient Q1 FY26 performance, with revenue increasing to ₹534 crore. The company’s Bio-based Chemicals segment saw a 43% year-on-year EBITDA growth, reaching ₹12.53 crore. Ethanol production reached 26,057 KL, driven by the restoration of B-heavy molasses-based ethanol production. Despite seasonal challenges, the company advanced its drug discovery portfolio, securing patents in Europe and China for novel anti-cancer molecules. The European patent has been validated in several countries, and safety trials have concluded without dose-limiting toxicity. The Chinese patent is for a compound that has shown strong efficacy against various cancers.
GBL’s profit after tax (PAT) declined to ₹16 crore, down from ₹26.1 crore in the same period last year. However, the company remains focused on strengthening its bio-based chemicals portfolio through debottlenecking, developing specialty chemicals, and expanding multi-feedstock ethanol capabilities. CMD Samir Somaiya emphasized the company’s commitment to investing in R&D for sustainable, long-term growth. Overall, GBL’s Q1 FY26 performance demonstrates its ability to navigate seasonal challenges and drive growth in its core segments.